Dense breast tissue makes breast health screening more challenging.  

SureTouch is able to overcome the density challenge because it measures tissue hardness or elasticity, rather than density.  

 

Fibrocystic and glandular tissue can be soft or hard depending on the hormonal cycle.

SureTouch determines the hardness of tissue and compares it with surrounding tissue. It is generally recommended that patients with hard, lumpy tissue return in two weeks for a second exam. A second exam will allow the provider to isolate lumps that are the result of hormonal changes from those that require diagnostic screening.

 

At-risk women benefit from clinical breast exams at frequent intervals as opposed to the routine regimen of once a year.

According to the American Cancer Society, “5% to 10% of breast cancer cases are thought to be hereditary, meaning that they result directly from gene defects (called mutations) inherited from a parent.”(1)

Having a family history of breast cancer significantly increases the risk of developing breast cancer. It has been estimated that women who have tested positive for the gene mutation BRCA1 have a 65% chance of developing breast cancer and those with BRCA2 a 45% chance. (2)(3)

The sensitivity, accuracy and immediacy of SureTouch combined with the fact that the exam is radiation free  makes SureTouch the right choice for women with increased risk of breast cancer.

(1) http://www.cancer.org/cancer/cancercauses/geneticsandcancer/heredity-and-cancer
(2) 
http://www.stopcancerfund.org/p-breast-cancer/brca1-and-brca2-mutations-when-your-genes-increase-your-cancer-risk/
(3) 
http://www.ncbi.nlm.nih.gov/pubmed/17416853

 

1 in 229 women under the age of 40 are at risk for developing breast cancer.

The American Cancer Society recommends that women do not have mammograms before the age of 40. The recommendation is based on concerns about the effects of radiation exposure at an early age and because younger women tend to have dense breast tissue.

However, 10% of all breast cancers are diagnosed in women under the age of 45. This means that every year 20,000 women under the age of 45 are diagnosed with breast cancer before undergoing any effective breast cancer screening. 

The sensitivity, accuracy and immediacy of SureTouch combined with the fact that the exam is radiation free makes SureTouch the right choice for younger women. In addition, unlike a manual CBE, SureTouch exams are digitally stored for future reference. This allows younger women to develop a breast health baseline with their first exam.